Eisai to Unveil New Research on Lecanemab for Early Alzheimer’s Treatment at AAN 2026

Eisai’s Groundbreaking Findings on Lecanemab at AAN 2026

Eisai Inc. has announced that it will unveil the latest research findings regarding Lecanemab, its anti-amyloid beta (Aβ) protofibril antibody developed for Alzheimer’s disease (AD), at the upcoming 2026 American Academy of Neurology (AAN) Annual Meeting. This significant event will take place from April 18 to 22 in Chicago and will also be accessible online.

At the AAN 2026, Eisai will present its findings through a series of 14 presentations, encompassing both oral and poster formats. Among these will be four key oral presentations that will showcase the depth of research on Lecanemab, focusing on mechanistic insights, biomarker explorations, and advancements in treatment delivery methods, alongside long-term clinical outcomes.

Focused Sessions on Alzheimer’s Therapeutics

One of the major highlights will be Eisai’s sponsorship of an Industry Therapeutic Update titled "Smoldering Alzheimer's Disease: The Ongoing Benefit of Addressing Multiple Pathologies." Scheduled on April 20, this two-part symposium features prominent experts discussing the concept of smoldering AD—a slow-developing condition that can begin decades before overt symptoms appear. In this session, attendees will learn how anti-amyloid therapies, like Lecanemab, address multifaceted aspects of AD beyond mere plaque removal.

The symposium aims to provide practical insights for healthcare professionals that will aid in the early detection of Alzheimer's. The data presented will be pivotal for fostering more informed conversations between healthcare providers and patients or their caregivers regarding the evolving treatment landscape for Alzheimer's disease.